News&Announcements

  • HOME
  • Introduction
  • News&Announcements
news view
Subject Research Center for Regenerative Medicine of Korea University Signed an MOU with MD Healthcare and Ucaretron
Selection News Date 2020-03-30 Read 62

Research Center for Regenerative Medicine

 

of Korea University Signed an MOU with

 

MD Healthcare and Ucaretron

 

 

Using an extracellular vesicle diagnostic platform, it will be possible

 

to predict disease from urine alone

 

 

Research Center for Regenerative Medicine of Korea University

 

(Director Moon Du-geon, Professor of Department of Urology of Korea

 

University Guro Hospital) signed a strategic MOU on the development

 

of new medical technology with MD Healthcare (CEO Kim Yoon Keun),

 

a firm specializing in extracellular vesicles, and Ucaretron (CEO Jang

 

Jee Hwan), a firm specializing in electronic medical device and AI, on

 

the last 26th.

 

 

The signing ceremony was held at MD Healthcare and attended by

 

Director Moon Du-geon of Research Center for Regenerative Medicine

 

of Korea University, CEO Kim Yoon Keun of MD Healthcare and CEO

 

Jang Jee Hwan of Ucaretron discussing joint research and development.

 

 

The agreement was concluded to expand the nanovesicle-based disease

 

diagnostic platform which was accumulated by MD Healthcare for the

 

past 10 years and apply it in urologic disease diagnostics for the first

 

time in the world. MD Healthcare’s extracellular vesicle diagnostic

 

platform which was invited to JP Morgan Biotech Showcase 2020 is a

 

new diagnostic technology that can predict about 20 diseases such as

 

depression, dementia, stomach cancer, and lung cancer with up to 98%

 

of accuracy by identifying the correlation between the distribution of

 

intestinal microflora and disease with AI through analysis of urine or

 

blood.

 

 

A research team led by Director Moon Du-geon of Research Center for

 

Regenerative Medicine of Korea University has been leading the

 

development of diagnostic and treatment technologies for domestic and

 

foreign urologic diseases. By systematically studying the correlation

 

between urologic diseases such as cystitis, prostatitis, erectile

 

dysfunction, and prostate cancer and intestinal microflora through

 

extracellular vesicles, it has become possible to develop unique new

 

medical technology thanks to the cooperative relations. The urologic

 

diseases’ extracellular vesicle-based intestinal microflora database which

 

will be collected in the future is expected to create a new interpretation

 

map for human disease by converging with 50,000 other large-scale

 

disease databases that have been accumulated so far.

 

 

“Through this research, it is possible to diagnose urological disease with

 

simple urine analysis, and we intend to secure the world’s first treatment

 

method that considers prebiotics and postbiotics,” Director Moon Du-

 

geon Stated. “This could be a gamechanger in urological medical

 

technology.”

 

 

“So far, the understanding of the disease has been achieved through a

 

traditional medical classification system. But the extracellular vesicle

 

approach can give new interpretations based on the interaction of

 

vesicles that are only tens of nanometer in size. With this cooperation,

 

we expect to further advance the diagnostic platform for extracellular

 

vesicles by improving the data of urologic diseases,” CEO Kim Yoon

 

Keun of MD Healthcare said.

 

 

Ucaretron will be in charge of AI analysis of large-volume of data

 

generated by the study, development of a new algorithm for tabular data

 

processing, and development of derived diagnostic devices.

 

File
Contents manager